In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar

Executive Summary

Amgen and Allergan’s biosimilar version of Herceptin has been approved by the US Food and Drug Administration.

You may also be interested in...



US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch

Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.

Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US

Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.

Amgen Withdraws EU Application For Its Infliximab Biosimilar

In a change of strategy, Amgen has withdrawn its European application for biosimilar infliximab.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel